Summary
This cohort study used the TriNetX health research database (69 US health care organizations) to identify adults aged ≥18 years with confirmed SARS-CoV-2 between January 1, 2020 and July 20, 2023. Of 3,029,340 people with confirmed SARS-CoV-2 infection, 13,214 were people with HIV (PWH), and 989 (7.5%) of PWH had documented at least 1 dose of any COVID-19 vaccine. The vaccination analysis compared vaccinated with unvaccinated PWH; vaccine type, number of doses, and duration were not reported, and outcomes were assessed at least 28 days following the first COVID-19 diagnosis. In Table 4, vaccinated PWH had lower odds than unvaccinated PWH for mortality (OR 0.29, 95% CI 0.19-0.46), diabetes (0.65, 0.43-0.99), heart disease (0.58, 0.4-0.85), mental disorders (0.66, 0.43-1.00), respiratory symptoms (0.82, 0.7-0.95), gastrointestinal symptoms (0.78, 0.67-0.9), fatigue (0.81, 0.67-0.98), chest pain (0.73, 0.61-0.87), and disturbances to smell and taste (0.47, 0.22-1.01). No significant differences were reported for hypertension, thyroid disorders, malignancy, thrombosis, rheumatoid arthritis, headache, bodyache, cognitive impairment, chronic cough, brain fog, palpitations, dizziness, hair loss, abnormal movements, or sexual desire or capacity. Harms and withdrawals were not reported. The abstract reported mortality OR 0.63 (95% CI 0.42-0.93) and fatigue OR 0.82 (95% CI 0.67-0.98), differing from the results/Table 4 values above.